Loading patent…
AssigneeSalus Mundi Investments Limited
InventorLuis Orlando Castro Cabrera
Estimating the term…
The present invention provides a consortium of resistant microorganisms for biodegrading carbohydrates in the organic fraction of any source of solid waste. The genetic, metabolic and morphological structure of these resistant microorganisms works efficiently by biodegrading and mineralising solid biodegradable waste from municipal or harvest solid waste, reducing the production of gases and leachates. This compound enriches and increases the concentration of beneficial microorganisms, generating high-quality biological fertilisers suitable for use in agricultural production, in land recovery and conservation, under the parameters established in sustainable organic farming, which seeks to conserve, recover and use nature or the environment without generating the least negative impact.
A consortium of microorganisms, wherein the microorganisms are initially exposed to a series of increasing fractions of a lethal dose of thiodicarb, subsequently exposed to a series of increasing fractions of a lethal dose of bifenthrin, wherein subsequent to the exposures of thiodicarb and bifenthrin, the microorganisms of the consortium are resistant to 1 to 1.3 times the lethal dose of thiodicarb and bifenthrin, wherein the consortium was deposited with the National Center of Genetic Resources (CM-CNRG) under accession number CM-CNRG TB44.
A consortium of microorganisms, wherein the microorganisms are initially exposed to increasing first fractions of a lethal dose of thiodicarb, subsequently exposed to increasing first fractions of a lethal dose of bifenthrin, subsequently exposed to increasing second fractions of a lethal dose of thiodicarb, wherein the second fractions of a lethal dose of thiodicarb are greater than the first fractions of a lethal dose of thiodicarb, subsequently exposed to increasing second fractions of a lethal dose of bifenthrin, wherein the second fractions of a lethal dose of bifenthrin are greater than the first fractions of a lethal dose of bifenthrin, subsequently exposed to increasing third fractions of a lethal dose of thiodicarb, wherein the third fractions of a lethal dose of thiodicarb are greater than the second fractions of a lethal dose of thiodicarb, subsequently exposed to increasing third fractions of a lethal dose of bifenthrin, wherein the third fractions of a lethal dose of bifenthrin are greater than the second fractions of a lethal dose of bifenthrin, subsequently exposed to increasing fourth fractions of a lethal dose of thiodicarb, wherein the fourth fractions of a lethal dose of thiodicarb are greater than the third fractions of a lethal dose of thiodicarb, subsequently exposed to increasing fourth fractions of a lethal dose of bifenthrin, wherein the fourth fractions of a lethal dose of bifenthrin are greater than the third fractions of a lethal dose of bifenthrin, subsequently exposed to increasing fifth fractions of a lethal dose of thiodicarb, wherein the fifth fractions of a lethal dose of thiodicarb are greater than the fourth fractions of a lethal dose of thiodicarb, and subsequently exposed to increasing fifth fractions of a lethal dose of bifenthrin, wherein the fifth fractions of a lethal dose of bifenthrin are greater than the fourth fractions of a lethal dose of bifenthrin, wherein subsequent to the first through fifth exposures of thiodicarb and the first through fifth exposures of bifenthrin, the microorganisms of the consortium are resistant to 1 to 1.3 times the lethal dose of thiodicarb and bifenthrin, wherein the consortium was deposited with the National Center of Genetic Resources (CM-CNRG) under accession number CM-CNRG TB44.
Dependencies are inferred from the claim text.